Lung Cancer Treatment by Stage

Before stage matters, the type does. Small cell lung cancer and non-small cell lung cancer are treated on entirely different tracks, and small cell does not even use stage numbers in routine practice. It uses limited stage and extensive stage.

Within non-small cell disease, NCI puts adenocarcinoma at about 40% of lung cancers, squamous cell carcinoma at about 25%, and large cell carcinoma at about 10%. That subtype decides which drugs are usable later.

The rest of this page follows the non-small cell path, with a note at the end on small cell.

For a small peripheral tumor, the operation itself has been tested.

A phase III noninferiority trial randomized 697 patients with clinical T1a N0 tumors under 2 cm to either lobar resection, removing a whole lobe, or sublobar resection, removing a segment or a wedge. Node-negative status in the hilar and mediastinal nodes was confirmed during the operation before randomization.

After a median follow-up of 7 years, sublobar resection was noninferior for disease-free survival. Lung function differed. At 6 months, the drop in predicted FEV1, the volume you can blow out in one second, was 6% after lobectomy and 4% after sublobar resection. Predicted FVC fell 5% versus 3%.

Those gaps are small in absolute terms and can matter a lot if your breathing is already limited. Ask which operation is planned and why.

For people who cannot have surgery, stereotactic body radiation therapy delivers a high dose in few sessions. In the largest reported series, 676 patients with T1 to T2 tumors were treated with three-, five-, or eight-fraction schedules chosen by how close the tumor sat to critical organs. At a median follow-up of 32.9 months, median overall survival was 40.7 months and 2-year local control was 95%.

Tumor location constrains the schedule. NCI notes that central location is a contraindication to the three-fraction approach, based on a phase II study that found excessive toxicity there.

Chemotherapy after surgery is standard for many resected stage II and IIIA cancers. What is newer is that the molecular result can change what comes next even after a complete resection.

The ADAURA trial randomized patients with resected EGFR-mutated disease, specifically exon 19 deletions or the L858R change, to osimertinib by mouth daily or placebo for up to 3 years. If this is offered to you, the strength on your own prescription is the one to follow, and it is reduced when side effects require it. Adjuvant chemotherapy was allowed but not required. The 5-year overall survival rate was 88% with osimertinib and 78% with placebo.

Osimertinib is a daily tablet taken at home. The trial's amount is quoted here as background; what you take is set by your own lung cancer team and written on your prescription.

NCI also cites alectinib in resected ALK-positive disease, and pembrolizumab versus placebo after complete resection of stage IB to IIIA cancer.

The practical point: molecular testing is not only for metastatic disease. Ask whether your resected tumor was tested. EGFR mutation in lung cancer explains what that report says.

Stage III covers everything from a tumor invading a neighboring structure to disease in mediastinal nodes. Some of it can be removed, some cannot, and the decision needs a multidisciplinary discussion rather than one clinician's judgment.

For unresectable stage III, the pattern is chemotherapy and radiation given together, then consolidation immunotherapy. The PACIFIC trial enrolled 713 patients whose disease had not progressed after platinum-based chemoradiation. They received durvalumab intravenously, or placebo, for up to a year; the strength and interval are set by the treating team.

Median progression-free survival was 16.9 months with durvalumab and 5.6 months with placebo. Estimated 5-year overall survival was 42.9% versus 33.4%. Grade 3 or 4 side effects occurred in 29.9% versus 26.1%, with pneumonia the most common at 4.4% versus 3.8%.

If your tumor carries an EGFR variant, the LAURA trial tested osimertinib rather than durvalumab after chemoradiation. That is a separate path, decided by the molecular report.

For resectable stage II to IIIB disease, the AEGEAN trial added durvalumab to chemotherapy before surgery, then continued it afterward. The trial excluded people with known EGFR or ALK alterations. At the first interim analysis, with only 31.9% data maturity and a median follow-up of 1 year, 12-month event-free survival was 73.4% in the durvalumab arm. Early data, presented honestly, are still early data.

At stage IV the first question is not which chemotherapy. It is which alteration.

NCI lists genes that can be matched to approved or developing drugs: EGFR, ALK, BRAF, ROS1, RET, NTRK1, NTRK2, NTRK3, MET, KRAS, and HER2. Frequencies vary widely. EGFR exon 19 deletions or L858R appeared in 52% of never-smokers in one series of 2,142 adenocarcinomas, versus 6% of current smokers. ALK fusions occur in 3% to 7% of unselected cases, ROS1 fusions in up to 2%, NTRK fusions in up to 1%.

If no driver is found, PD-L1 level and subtype guide the choice between immunotherapy alone and immunotherapy plus chemotherapy. Keytruda and chemotherapy covers the trials behind those combinations, including why EGFR and ALK positive tumors were excluded from them.

Stage 4 lung cancer: what now covers the M1a, M1b, and M1c distinctions that sit underneath the single word "stage 4."

Limited stage means the cancer fits within one radiation field. Extensive stage means it does not.

For limited stage, chemotherapy and chest radiation are given together. NCI reports Intergroup 0096, which compared twice-daily radiation to 45 Gy over three weeks against once-daily 45 Gy over five weeks, both alongside cisplatin and etoposide. Five-year survival was 26% versus 16%, with more esophagitis on the twice-daily arm. Finishing radiation in under 30 days was associated with better five-year survival.

NCI also reports that treatment-related death in one trial was 1% under age 70 and 10% at 70 or older. Cisplatin and etoposide covers what those cycles involve.

SEER's stat facts page for lung and bronchus cancer, using cases diagnosed from 2016 to 2022, reports 5-year relative survival of 65.5% for localized disease, 38.2% for regional, and 10.5% for distant. Across all stages it is 29.5%.

NCI's clinician summary has not yet moved to that window. It still rounds the earlier 2014 to 2020 cohort: 64% local, 36% regional, 9% distant, and 27% across all stages.

So the two pages describe the same disease from cohorts six years apart. What matters more is what the window means. These figures describe people diagnosed years ago, before several current drugs were routine, and they pool every subtype and biomarker group together. A number built that way cannot tell you your own outlook. Ask your team what it looks like for your stage, your subtype, and your molecular result.

• You cough up blood, more than streaks.
• Breathlessness worsens over hours, or you are breathless sitting still.
• Your face, neck, or an arm swells and chest veins become prominent.
• New back pain comes with leg weakness, numbness, or bladder trouble.
• Your temperature reaches 100.4 degrees F (38 C). MedlinePlus, reviewed October 2024, uses 100.4 F; NCI's infection page, reviewed January 2020, uses 100.5 F. Use the lower, newer number.

• https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq
• https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq
• https://seer.cancer.gov/statfacts/html/lungb.html
• https://www.cancer.gov/about-cancer/treatment/side-effects/infection
• https://medlineplus.gov/ency/patientinstructions/000913.htm